DUBLIN–(BUSINESS WIRE)–The “Heart Failure – Pipeline Insight” clinical trials has been added to ResearchAndMarkets.com’s offering.
This “Heart Failure – Pipeline Insight, 2022” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Heart Failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
“Heart Failure – Pipeline Insight, 2022” report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart Failure pipeline landscape is provided which includes the disease overview and Heart Failure treatment guidelines.
The assessment part of the report embraces, in depth Heart Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence in Heart Failure R&D. The therapies under development are focused on novel approaches to treat/improve in Heart Failure.
- In March 2022, Lexicon Pharmaceuticals entered into a loan facility with Oxford Finance LLC that provides up to $150 million in borrowing capacity designed primarily to support commercial preparations and the potential launch of sotagliflozin in heart failure.
- In MAY 2021, Heartseed and Novo Nordisk entered into global collaboration and license agreement for stem cell-based therapy for heart failure. Novo Nordisk gains exclusive rights to develop, manufacture and commercialise HS-001 worldwide except in Japan. Heartseed will maintain the rights to solely develop HS-001 in Japan and Novo Nordisk has the rights to co-commercialise the product in Japan with Heartseed with 50/50 profit and cost sharing. Heartseed is eligible to receive payments totalling up to 598 million US dollars including 55 million dollars in upfront and near-term milestone payments. Heartseed is also eligible to receive tiered high single-digit to low double-digit royalties of annual net sales outside of Japan.
- In January 2022, BenevolentAI and AstraZeneca have announced the expansion of their artificial intelligence (AI)-powered drug discovery partnership to include disease areas, systemic lupus erythematosus (SLE) and heart failure (HF). The three-year collaboration extension comprises an upfront payment, funding for research, payments on meeting development milestones and tiered royalty payments on revenues in the future.
- In January 2021, Lexicon Pharmaceuticals received feedback from the FDA that the results of the SOLOIST and SCORED studies can support the submission of an application for regulatory approval for an indication to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure.
- In March 2022, BioCardia, Inc., announced the designation of a new reimbursement code for the CardiAMP Cell Therapy procedure to transplant autologous bone marrow cells to treat heart failure from the U.S. Center for Medicare and Medicaid Services (CMS).
- In February 2022, BioCardia, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Device Designation for the CardiAMP Cell Therapy System for the treatment of heart failure. It is believed to be the first cardiac cell therapy to receive FDA Breakthrough Device status.
Heart Failure Emerging Drugs
Tirzepatide: Eli Lilly and Company
Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on glucose and body weight. Tirzepatide is in phase 3 development for chronic weight management and heart failure with preserved ejection fraction (HFpEF). It is also being studied as a potential treatment for non-alcoholic steatohepatitis (NASH). Both the FDA and EMA have accepted Eli Lilly’s marketing approval applications for its type 2 diabetes treatment, tirzepatide.
Finerenone (BAY94-8862): Bayer
Finerenone (BAY 94-8862) is an investigational novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that has been shown to block the harmful effects of the overactivated mineralocorticoid receptor (MR) system. MR overactivation is a major driver of heart and kidney damage. Current steroidal MRAs on the market have proven to be effective in reducing cardiovascular mortality in patients suffering from heart failure with reduced ejection fraction (HFrEF). However, they are often underutilized due to the incidence of hyperkalemia, renal dysfunction, and anti-androgenic/ progestogenic side effects.
CardiAMP Cell Therapy: BioCardia
CardiAMP Cell Therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response. The CardiAMP Cell Therapy Heart Failure Trial is the first multicenter clinical trial of an autologous cell therapy to prospectively screen for cell therapeutic potency in order to improve patient outcomes. CardiAMP Cell Therapy incorporates three proprietary elements not previously utilized in investigational cardiac cell therapy, which the company believes improves the probability of success of the treatment: a pre-procedural diagnostic for patient selection, a high target dosage of cells, and a proprietary delivery system that has been shown to be safer than other intramyocardial delivery systems and more successful for enhancing cell retention.
Rexlemestrocel-L (Revascor): Mesoblast
Revascor consists of 150 million mesenchymal precursor cells (MPCs) administered by direct injection into the heart muscle in patients suffering from CHF and progressive loss of heart function. MPCs release a range of factors when triggered by specific receptor-ligand interactions within damaged tissue. Based on preclinical data, it is believed that these factors induce functional cardiac recovery by simultaneous activation of multiple pathways, including induction of endogenous vascular network formation, reduction in harmful inflammation, reduction in cardiac scarring and fibrosis, and regeneration of heart muscle through activation of tissue precursors.
BMS-986231: Bristol-Myers Squibb
Cimlanod (development codes CXL-1427 and BMS-986231) is an experimental drug for the treatment of acute decompensated heart failure. HNO gas (nitroxyl) is a chemical sibling of nitric oxide. Although nitric oxide and HNO appear to be closely related chemically, the physiological effects and biologic mechanisms of HNO and nitric oxide action are distinct. The biologic effects of HNO are mediated by direct post-translational modification of thiol residues in target proteins, including SERCA2a, phospholamban, the ryanodine receptor, and myofilament proteins in cardiomyocytes. In vitro, HNO increases the efficiency of calcium cycling and improves myofilament calcium sensitivity, which enhances myocardial contraction and relaxation. HNO also mediates peripheral vasodilation through endothelial soluble guanylate cyclase. HNO does not induce tachyphylaxis in peripheral vessels, unlike nitric oxide.
Elamipretide: Stealth BioTherapeutics
Elamipretide (MTP-131, Bendavia) is a novel tetra-peptide that targets mitochondrial dysfunction in energydepleted myocytes. Elamipretide crosses the outer membrane of the mitochondria and associates itself with cardiolipin, which is a phospholipid expressed only in the inner membrane of mitochondria. Cardiolipin has an integral role in mitochondrial stability and organization of respiratory complexes into super complexes for oxidative phosphorylation.Thus, elamipretide helps to enhance ATP synthesis in multiple organs of the body. Elamipretide has been shown to improve left ventricular ejection fraction (LVEF), LV end diastolic pressure, cardiac hypertrophy, myocardial fibrosis, and myocardial ATP synthesis in both animal models and humans.
FA relaxin: Bristol Myers Squibb
BMS-986259 is a next-generation version of Relaxin that is enabled with our technology and currently in Phase 1 clinical trials for ADHF. Relaxin, a peptide hormone, has been reported to reduce fibrosis in the multiple organs and to exert cardioprotective effects in preclinical studies. However, the therapeutic potential of Relaxin has been partially limited by its short half-life in humans. BMS-986259 has exhibited a prolonged half-life and therefore has the potential to enhance clinical benefit as a novel therapeutic for ADHF.
Key Players
- Eli Lilly and Company
- Bayer
- BioCardia
- Mesoblast Inc.
- Janssen Research & Development
- Pfizer
- Bristol-Myers Squibb
- Actelion Pharmaceuticals
- Tasly Pharmaceuticals
- Ionis Pharmaceuticals
- Innolife
- Imara Inc
- Bristol-Myers Squibb
- Stealth BioTherapeutics
- Bristol Myers Squibb
- Berlin Cures
- Bayer
- AstraZeneca
- Regeneron Pharmaceuticals
- GlaxoSmithKline
- SQ Innovation
- Recardio
- BIAL
- AstraZeneca
- Bristol Myers Squibb
- Imbria Pharmaceuticals
- Tenaya Therapeutics
- Ribomic
Key Products
- Tirzepatide
- Finerenone (BAY 94-8862)
- CardiAMP cell therapy
- Rexlemestrocel-L (Revascor)
- Rivaroxaban
- Sildenafil citrate
- Mavacamten
- Macitentan
- Qishenyiqi Dripping Pills
- IONIS-AGT-LRx
- INL 1
- IMR-687
- BMS-986231
- Elamipretide
- FA relaxin
- BC-007
- Pecavaptan
- AZD-8601
- REGN5381
- GSK3884464
- SQIN-01
- REC 02
- Zamicastat
- AZD-3427
- ROMK inhibitor
- IMB-101
- TN-301
- RBM-003
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/soc45u
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900